This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Piper Sandler Sticks to Its Buy Rating for enGene Holdings (ENGN)

Tipranks - Tipranks - Sat May 2, 6:20AM CDT

Piper Sandler analyst Allison Bratzel maintained a Buy rating on enGene Holdings today and set a price target of $26.00.

Claim 55% Off TipRanks

According to TipRanks, Bratzel is a 5-star analyst with an average return of 42.9% and a 58.97% success rate. Bratzel covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Travere Therapeutics, and Akebia Therapeutics.

In a report released on April 29, H.C. Wainwright also maintained a Buy rating on the stock with a $25.00 price target.

See today’s best-performing stocks on TipRanks >>

Based on enGene Holdings’ latest earnings release for the quarter ending January 31, the company reported a quarterly GAAP net loss of $29.75 million. In comparison, last year the company had a GAAP net loss of $24.62 million

Read More on ENGN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).